TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study using Medicaid and commercial insurance records found no overall increase in major congenital malformations among live-born infants whose mothers filled benzodiazepine prescriptions in the first trimester. The authors say the findings are reassuring for major birth defects, while other medication risks and outcomes such as miscarriage and neonatal effects remain unresolved.
A U.S. study of more than 4 million pregnancies found no significant increase in major congenital malformations among live-born infants whose mothers filled a benzodiazepine prescription during the first trimester, compared with pregnancies without those fills. The findings, published in Annals of Internal Medicine, add evidence for clinicians and patients weighing medication decisions during pregnancy, but do not establish that benzodiazepines are risk-free.
The researchers pooled data from two insurance populations: more than 2.4 million Medicaid-insured pregnancies and about 1.7 million commercially insured pregnancies. They identified pregnancies with at least one filled benzodiazepine prescription in the first trimester and compared them with pregnancies without a fill in the three months before the last menstrual period. The analysis included a range of medications, including alprazolam, clonazepam, diazepam and lorazepam.
The pooled adjusted relative risk for any congenital malformation was 0.99 (95% confidence interval 0.96 to 1.03), showing no statistically significant difference between exposed and unexposed groups. Adjusted absolute risks were 4.0% versus 4.1% in the Medicaid data and 4.9% versus 4.8% in the commercial insurance data. The study also found no consistent overall differences for the organ-specific outcomes it assessed, including cardiac, oral cleft, gastrointestinal, central nervous system and eye malformations.
Results were broadly similar in sensitivity analyses that considered multiple first-trimester fills, dose and different benzodiazepines. The researchers did report an increased eye-malformation risk signal for diazepam in the commercially insured group, as well as some elevated risks for particular malformations among people also taking other psychoactive medications. These findings did not form a consistent pattern across the analyses.
Evidence for Pregnancy Medication Decisions
Benzodiazepines are prescribed for conditions including anxiety, and the study addresses a gap in evidence that has left patients and clinicians weighing earlier research with mixed results. About one in five women experience anxiety disorders during pregnancy and postpartum, according to the report. Better estimates of possible fetal risks can inform discussions about treatment, while untreated serious psychiatric conditions also carry consequences that need to be considered.
The findings offer reassurance specifically about major congenital malformations among live births in the populations studied. They do not answer whether continuing or starting a benzodiazepine is appropriate for a particular patient. The researchers note that these drugs can also involve dependence, misuse, cognitive adverse effects and withdrawal, so decisions require individual clinical assessment.
Products Worth Considering
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
Therabody Theragun Mini 3rd Generation Percussive Massage Gun, Black
Oura Ring 5 Smart Ring, Gold, Size 8
As an affiliate, we earn on qualifying purchases.
Why Earlier Safety Evidence Was Limited
Previous studies of benzodiazepines and congenital malformations were described by the report as small and conflicting. The research team used two large U.S. insurance databases to compare prescription fills and coded malformation diagnoses, adjusting its estimates to account for measured differences between groups. In both insurance cohorts, the exposed group tended to be older and to have more psychiatric and chronic health conditions than the unexposed group.
The analysis was a population-based cohort study, not a randomized trial. Exposure was defined by a filled prescription, which does not prove that a patient took the medication. The researchers linked pregnant patients to infants and required insurance coverage around pregnancy and after birth; the findings therefore reflect the study’s insured populations and eligibility criteria.
“This study provides the most comprehensive U.S. evidence to date on benzodiazepine use early in pregnancy and major congenital malformations.”
— Krista Huybrechts, MS, PhD, co-author, speaking to MedPage Today
Risks Beyond Live-Birth Defects
The study included live births only. It could not capture severe malformations associated with miscarriage, stillbirth or pregnancy termination, so its results do not describe all pregnancies. Prescription fills also do not confirm that a medication was taken, some malformation cases may have been missed, and residual confounding—differences between groups that the analysis could not fully account for—remains possible.
The study does not settle questions about miscarriage, preterm birth or effects on newborns. Nor do the overall findings rule out risks for particular medications, doses, combinations or uncommon outcomes. The isolated diazepam eye-malformation signal and results involving co-exposure need cautious interpretation; the report does not establish that these associations are causal.
Further Pregnancy Outcomes Need Study
The authors said further research should examine outcomes beyond major birth defects, including miscarriage, preterm birth and neonatal effects. Additional evidence may help clarify whether risks differ by specific benzodiazepine, dose, timing or use alongside other psychoactive medicines.
For now, the study supports discussions between patients, obstetric clinicians and mental health providers rather than a blanket treatment rule. The American College of Obstetricians and Gynecologists recommends that mental health treatment during pregnancy be determined collaboratively by mental health and obstetric providers, according to the report. How a patient should manage a current prescription depends on their circumstances and should be discussed with their care team.
Key Questions
What did the study find about benzodiazepines in the first trimester?
Among live-born infants, the study found no significant overall increase in major congenital malformations when mothers had filled a benzodiazepine prescription in the first trimester. The pooled adjusted relative risk was 0.99, with a 95% confidence interval of 0.96 to 1.03.
Does this mean benzodiazepines are risk-free during pregnancy?
No. The findings address major congenital malformations in live births. The study did not assess every potential outcome, and its co-author noted concerns including dependence, misuse, cognitive adverse effects and withdrawal.
How many pregnancies did researchers study?
The analysis included more than 4 million pregnancies from Medicaid and commercial insurance databases: over 2.4 million publicly insured pregnancies and about 1.7 million commercially insured pregnancies.
What outcomes were not resolved by this study?
Because the analysis was restricted to live births, it could not assess malformations linked to miscarriages, stillbirths or pregnancy terminations. The authors also called for research into miscarriage, preterm birth and neonatal effects.
Should someone stop taking a benzodiazepine because of these findings?
The study does not provide individual treatment instructions. Decisions about mental health treatment during pregnancy should be discussed with the patient’s obstetric and mental health providers, taking into account the person’s condition and treatment options.
Source: rss
